Okhla, Delhi
- GST NO. : 07ABEFM6994Q2Z7
Thyroid Cancer
Leading Exporters and Wholesaler of Lenvatinib Capsules and Vandetanib Tablets from Delhi.
| Business Type | Exporter, Supplier |
| Dosage Form | Capsules |
| Treatment | Cancer |
| Dosage | As per Doctor's Prescription |
| Storage | Cool and Dry Place |
| Best Before | 36 Months from Manufacturing |
Preferred Buyer From
| Location | Worldwide |
FDA grants regular approval to sacituzumab govitecan for triple-negative breast cancer.On April 7, 2021, the Food and Drug Administration granted regular approval to sacituzumab govitecan (Trodelvy, Immunomedics Inc.) for patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.
Sacituzumab govitecan (Trodelvy): In the case of this ADC, the monoclonal antibody part attaches to the Trop-2 protein on breast cancer cells and brings a chemo drug, similar to irinotecan, directly to them. (Some breast cancer cells have too much Trop-2, which helps them grow and spread quickly.)
This antibody-drug conjugate can be used by itself to treat advanced TNBC, after at least 2 other chemo regimens have been tried. This drug is given in a vein (IV) weekly for 2 weeks, followed by one week off, then restarted.
| Business Type | Exporter, Supplier |
| Treatment | Cancer |
| Form | Tablets |
| Dosage | As per Doctor's Prescription |
| Storage | Cool and Dry Place |
| Best Before | 36 Months from Manufacturing |
Preferred Buyer From
| Location | Worldwide |
A drug used to treat medullary thyroid cancer that is locally advanced and cannot be removed by surgery or has spread to other parts of the body. It is also being studied in the treatment of other types of cancer. Vandetanib blocks certain proteins, which may help keep cancer cells from growing. It may also prevent the growth of new blood vessels that tumors need to grow. Vandetanib is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. Also called Caprelsa and ZD6474.
Vandetanib is approved to treat: Medullary thyroid cancer that cannot be removed by surgery and is locally advanced or has metastasized (spread to other parts of the body). Vandetanib, sold under the brand name Caprelsa, is an anti-cancer medication that is used for the treatment of certain tumours of the thyroid gland. It acts as a kinase inhibitor of a number of cell receptors, mainly the vascular endothelial growth factor receptor (VEGFR), the epidermal growth factor receptor (EGFR), and the RET-tyrosine kinase. The drug was developed by AstraZeneca who later sold the rights to Sanofi in 2015
